Drug Profile
Ronacaleret
Alternative Names: 751689; Ronacaleret Hydrochloride; SB-751,689; SB-751689-ALatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator NPS Pharmaceuticals
- Developer GlaxoSmithKline
- Class Osteoporosis therapies; Propionic acids; Small molecules
- Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fracture; Postmenopausal osteoporosis; Stem cell mobilisation
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 01 Mar 2016 Discontinued - Phase-I for Postmenopausal osteoporosis (In volunteers) in USA (PO) (NCT00651534)
- 21 Jul 2015 Discontinued - Phase-II for Stem cell mobilisation in USA (PO)